

[Radiother Oncol](#). 2024 Nov 16;202:110640. doi: 10.1016/j.radonc.2024.110640.

Online ahead of print.

An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors

Martin C Tom ¹, Seema Nagpal ², Joshua D Palmer ³, William G Breen ⁴, Erqi L Pollom ⁵, Eric J Lehrer ⁴, Tresa M McGranahan ⁶, Kevin Shiue ⁷, Anupama Chundury ⁸, Shearwood McClelland Iii ⁹, Hina Saeed ¹⁰, Eric L Chang ¹¹, Veronica L S Chiang ¹², Tony J C Wang ¹³, Jonathan P S Knisely ¹⁴, Samuel T Chao ¹⁵, Michael T Milano ¹⁶

Affiliations

PMID: 39557126 DOI: [10.1016/j.radonc.2024.110640](https://doi.org/10.1016/j.radonc.2024.110640)

Abstract

The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2-3 glioma.

Keywords: Astrocytoma; Grade 2 glioma; IDH inhibitor; Oligodendroglioma; Vorasidenib.

Copyright © 2024 Elsevier B.V. All rights reserved.

[PubMed Disclaimer](#)